Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2008. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of £11.17 per Ordinary share at the time of the transaction.
Material Changes
The material change reported is an increase in shareholdings for specific individuals following the re-investment of dividends paid on October 9, 2008. The specific increases are:
- Mr A P Witty: 28 shares
- Mrs C M Witty: 376 shares
- Mr J S Heslop: 378 shares
- Mrs P A Heslop: 92 shares
- Mr D Learmouth: 111 shares
- Dr D Pulman: 170 shares
- Mrs C R Pulman: 57 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of insider share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares held by the named directors and connected persons post-transaction.
- Confirm the dividend reinvestment plan details for the October 9, 2008 payment.
- Check the market price of GSK Ordinary shares on October 10, 2008, to validate the £11.17 transaction price.